<DOC>
	<DOCNO>NCT00478062</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor antigen may help body build effective immune response kill tumor cell . PURPOSE : This phase I/II trial study side effect well vaccine therapy work treat patient receive first-line therapy Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients Who Have Received First-Line Therapy Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine immunologic response patient complete first-line therapy Hodgkin 's lymphoma treat Hodgkin 's antigens-GM-CSF-expressing cell vaccine . - Determine durability immunologic responses patient . - Determine utility Epstein-Barr virus reporter system monitor cellular vaccine response . - Determine safety tolerability vaccine patient . OUTLINE : Beginning 4-6 month last chemotherapy , patient receive Hodgkin 's antigens-GM-CSF-expressing cell vaccine day 1 . Treatment repeat every 3 week 4 course . Immunologic responses serially monitor along disease status . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis classic Hodgkin 's lymphoma Must complete firstline therapy without evidence disease progression PATIENT CHARACTERISTICS : HIV negative PRIOR CONCURRENT THERAPY : See Disease Characteristics No 6 month since prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>